BeOne Medicines annual operating margin
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BeOne Medicines's operating margin was 8.37% for fiscal 2025.
View full BeOne Medicines company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 8.37% | +23.28 pp |
| 2024 | 2024-12-31 | −14.91% | +34.21 pp |
| 2023 | 2023-12-31 | −49.12% | +77.28 pp |
| 2022 | 2022-12-31 | −126.40% | −4.08 pp |
| 2021 | 2021-12-31 | −122.31% | +414.37 pp |
| 2020 | 2020-12-31 | −536.69% | −312.52 pp |
| 2019 | 2019-12-31 | −224.16% | +131.89 pp |
| 2018 | 2018-12-31 | −356.05% | −314.75 pp |
| 2017 | 2017-12-31 | −41.30% | +10898.89 pp |
| 2016 | 2016-12-31 | −10,940.19% | −10296.53 pp |
| 2015 | 2015-12-31 | −643.66% | −522.78 pp |
| 2014 | 2014-12-31 | −120.88% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 19.06% | +12.38 pp |
| Q1 2026 | 2026-03-31 | 16.51% | +15.52 pp |
| Q4 2025 | 2025-12-31 | 12.35% | +19.39 pp |
| Q3 2025 | 2025-09-30 | 11.55% | +23.56 pp |
| Q2 2025 | 2025-06-30 | 6.68% | +18.21 pp |
| Q1 2025 | 2025-03-31 | 0.99% | +35.76 pp |
| Q4 2024 | 2024-12-31 | −7.04% | +53.45 pp |
| Q3 2024 | 2024-09-30 | −12.01% | +5.14 pp |
| Q2 2024 | 2024-06-30 | −11.53% | +42.01 pp |
| Q1 2024 | 2024-03-31 | −34.77% | +48.14 pp |
| Q4 2023 | 2023-12-31 | −60.50% | +62.79 pp |
| Q3 2023 | 2023-09-30 | −17.15% | +95.94 pp |
| Q2 2023 | 2023-06-30 | −53.54% | +75.10 pp |
| Q1 2023 | 2023-03-31 | −82.91% | +61.66 pp |
| Q4 2022 | 2022-12-31 | −123.29% | +143.90 pp |
| Q3 2022 | 2022-09-30 | −113.09% | +110.86 pp |
| Q2 2022 | 2022-06-30 | −128.64% | +187.94 pp |
| Q1 2022 | 2022-03-31 | −144.57% | −156.15 pp |
| Q4 2021 | 2021-12-31 | −267.19% | +217.23 pp |
| Q3 2021 | 2021-09-30 | −223.95% | +259.29 pp |
| Q2 2021 | 2021-06-30 | −316.58% | +230.20 pp |
| Q1 2021 | 2021-03-31 | 11.58% | +729.53 pp |
| Q4 2020 | 2020-12-31 | −484.43% | +197.63 pp |
| Q3 2020 | 2020-09-30 | −483.24% | +139.53 pp |
| Q2 2020 | 2020-06-30 | −546.78% | −511.50 pp |
| Q1 2020 | 2020-03-31 | −717.95% | −494.71 pp |
| Q4 2019 | 2019-12-31 | −682.06% | −203.44 pp |
| Q3 2019 | 2019-09-30 | −622.78% | −344.00 pp |
| Q2 2019 | 2019-06-30 | −35.27% | +273.51 pp |
| Q1 2019 | 2019-03-31 | −223.24% | +117.25 pp |
| Q4 2018 | 2018-12-31 | −478.62% | −530.80 pp |
| Q3 2018 | 2018-09-30 | −278.78% | +8583.31 pp |
| Q2 2018 | 2018-06-30 | −308.78% | +5957.88 pp |
| Q1 2018 | 2018-03-31 | −340.49% | +2663.06 pp |
| Q3 2017 | 2017-09-30 | 52.18% | +616.13 pp |
| Q3 2016 | 2016-09-30 | −8,862.09% | −7848.17 pp |
| Q2 2016 | 2016-06-30 | −6,266.67% | −5790.94 pp |
| Q1 2016 | 2016-03-31 | −3,003.55% | −2292.01 pp |
| Q4 2015 | 2015-12-31 | −563.95% | — |
| Q3 2015 | 2015-09-30 | −1,013.91% | — |
| Q2 2015 | 2015-06-30 | −475.72% | — |
| Q1 2015 | 2015-03-31 | −711.53% | — |
Over the last five reported fiscal years, BeOne Medicines's operating margin increased from −536.69% to 8.37%, a change of +545.05 percentage points. The latest reported quarter, Q2 2026, shows 19.06%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BeOne Medicines filings at SEC.gov ↗